Murray Stahl's RPRX Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 354,685 shares of Royalty Pharma plc (RPRX) worth $12.51 M, representing 0.15% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in RPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2021, adding 163,492 shares. Largest reduction occurred in Q4 2023, reducing 70,565 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Royalty Pharma plc (RPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Royalty Pharma plc (RPRX) Trades by Murray Stahl
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2021 | +49,765 | New Buy | 49,765 | $43.63 |
| Q2 2021 | +163,492 | Add 328.53% | 213,257 | $40.99 |
| Q3 2021 | +27,071 | Add 12.69% | 240,328 | $36.14 |
| Q4 2021 | +42,209 | Add 17.56% | 282,537 | $39.85 |
| Q1 2022 | +108,381 | Add 38.36% | 390,918 | $38.96 |
| Q2 2022 | +62,638 | Add 16.02% | 453,556 | $42.04 |
| Q3 2022 | -45,010 | Reduce 9.92% | 408,546 | $40.18 |
| Q4 2022 | -8,666 | Reduce 2.12% | 399,880 | $39.52 |
| Q1 2023 | -26,760 | Reduce 6.69% | 373,120 | $36.03 |
| Q2 2023 | -39,451 | Reduce 10.57% | 333,669 | $30.74 |
| Q3 2023 | -46,414 | Reduce 13.91% | 287,255 | $27.14 |
| Q4 2023 | -70,565 | Reduce 24.57% | 216,690 | $28.09 |
| Q1 2024 | -16,402 | Reduce 7.57% | 200,288 | $30.37 |
| Q2 2024 | +28,496 | Add 14.23% | 228,784 | $26.37 |
| Q3 2024 | +12 | Add 0.01% | 228,796 | $28.29 |
| Q4 2024 | +90,380 | Add 39.50% | 319,176 | $25.51 |
| Q1 2025 | +10,394 | Add 3.26% | 329,570 | $31.13 |
| Q2 2025 | +23,901 | Add 7.25% | 353,471 | $36.03 |
| Q3 2025 | +1,214 | Add 0.34% | 354,685 | $35.28 |
Murray Stahl's Royalty Pharma plc Investment FAQs
Murray Stahl first purchased Royalty Pharma plc (RPRX) in Q1 2021, acquiring 49,765 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Royalty Pharma plc (RPRX) for 19 quarters since Q1 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl's largest addition to Royalty Pharma plc (RPRX) was in Q2 2021, adding 213,257 shares worth $8.74 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 354,685 shares of Royalty Pharma plc (RPRX), valued at approximately $12.51 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Royalty Pharma plc (RPRX) represents approximately 0.15% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl's peak holding in Royalty Pharma plc (RPRX) was 453,556 shares, as reported at the end of Q2 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.